Agilent acquires Biocare for $950M to boost pathology/cancer diagnostics and recurring revenue. Click here to read an analysis of A stock now.

Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with ...

The Central Board of Secondary Education (CBSE) conducted the Class 12 Mathematics exam on Monday (March 9). The exam was held from 10.30 am to 1.30 pm for CBSE students across India. Students and ...

BriteCo reports lab-grown diamonds now cost 73% less than natural ones, capturing over 45% of US engagement ring sales, ...

Gubra's partner AbbVie today announced positive topline results from the 12 and 13-weeks Phase 1 Multiple Ascending Dose (MAD) trial showing that ABBV-295 was well tolerated with a dose-dependent sign ...

Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...

The CBSE Class 12 Mathematics exam 2026 ranged from moderate to moderately difficult, according to teachers. The paper ...

The CBSE Class 12 Mathematics exam has been concluded, and students’ reactions along with a detailed paper analysis are now live. Initial responses suggest that the paper was balanced and largely in ...

Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.

Goldman Sachs recently named several stocks the Wall Street colossus believes are a must-own as market fears rise. The ...

The MarketWatch News Department was not involved in the creation of this content.-- Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which ...